Tag: Solid tumors

FDA approves Iovance’s AMTAGVI: A breakthrough in melanoma treatment

businessnewstoday- February 18, 2024

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made ... Read More

Advancing bladder cancer treatment: EMA scrutinizes Astellas-Pfizer’s innovative therapy

businessnewstoday- January 28, 2024

A groundbreaking development in bladder cancer treatment is on the horizon as Astellas Pharma Inc. and Pfizer Inc. await the European Medicines Agency’s (EMA) review ... Read More

Iksuda Therapeutics advances IKS014 in Phase 1 trial following positive initial results

businessnewstoday- October 24, 2023

Iksuda Therapeutics, a clinical-stage biotechnology firm from the UK specializing in innovative antibody drug conjugates (ADCs) for tumor specificity, reported successful completion of the first ... Read More

Exscientia begins enrollment for Phase 1/2 cancer trial of CDK7 inhibitor

businessnewstoday- July 11, 2023

AI-driven precision medicine company Exscientia has initiated enrollment for its Phase 1/2 "ELUCIDATE" study, marking the first trial of its precision-designed CDK7 inhibitor, GTAEXS617 ('617), ... Read More

Biomea Fusion to take BMF-219 into clinical trials for KRAS solid tumors

businessnewstoday- October 16, 2022

Biomea Fusion is all set to take BMF-219 into clinical trials in patients having unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal ... Read More

Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma

pallavi123- June 23, 2022

Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. ... Read More

BMS to acquire precision oncology company Turning Point Therapeutics for $4.1bn

pallavi123- June 14, 2022

Bristol Myers Squibb (BMS) has agreed to acquire Turning Point Therapeutics, a clinical-stage precision oncology company based in California, for $4.1 billion. Listed on the ... Read More

Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial

pallavi123- January 15, 2022

Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 ... Read More

TCR2 Therapeutics reports positive interim results for gavo-cel in early-stage solid tumors trial

pallavi123- September 18, 2021

TCR2 Therapeutics has reported positive interim results from its phase 1 part of the phase 1/2 clinical trial of its T-cell therapy candidate gavo-cel in ... Read More

Pfizer to acquire immuno-oncology company Trillium Therapeutics for $2.2bn

pallavi123- August 27, 2021

US pharma giant Pfizer has agreed to acquire Trillium Therapeutics, a publicly listed Canadian clinical stage immuno-oncology company, for $18.5 per share or $2.26 billion ... Read More